Notice of AGM

RNS Number : 2616R

Graft Polymer (UK) PLC

04 July 2022

 

4 July 2022

Graft Polymer (UK) Plc

("Graft Polymer", the "Company", and together with its subsidiaries, the "Group")

Notice of Annual General Meeting

Graft Polymer (UK) Plc (LSE: GPL), a business focused on the development and commercial production of polymer modification, biological supplements, and nano-drug delivery systems, announces that its Annual General Meeting ("AGM") will be held at the offices of Memery Crystal LLP, 165 Fleet Street, London EC4A 2DY on 28 July 2022 at 10am.

Notice of AGM and a Form of Proxy have been sent to the shareholders of the Company. The notice of AGM is also available on the Company's website https://graftpolymer.com/  

**ENDS**

For more information, please visit  https://www.graftpolymer.com  or contact:

Graft Polymer (UK) Plc	via Tavistock
Roby Zomer, Chairman
Yifat Steuer, CFO
Turner Pope Investments (Broker)	[phone]
James Pope
Andy Thacker
Tavistock (Public Relations)	[phone]
Heather Armstrong	[e-mail]
Katie Hopkins

About Graft Polymer

Graft Polymer is a UK incorporated holding company with an innovative research and manufacturing facility, based in Slovenia. The core business of the Group comprises polymer modification and drug delivery systems developments. Established in 2017, the Group has already introduced more than 50 products to the market.

The Group has developed a proprietary set of polymer modification technologies, which can improve existing products and processing methodologies by enhancing performance, simplifying manufacturing, reducing material consumption, widening the choice of feedstocks, and reducing costs.

In particular, the Group's techniques allow the combination of otherwise incompatible polymers, facilitating the creation of polymer composites engineered at a molecular level, that combine the attractive properties of different input materials. This enables customers to receive a synergism of properties in polymer composites.

The solutions and products offered by the Group are designed to improve performance, reduce raw materials consumption, and enhance the physical characteristic values of finished products or improve or modify their chemical interaction. In the past several years, there has been increased emphasis by the industry as a whole on applications of grafted polymers, which are produced by monomers being covalently bonded and polymerised as side chains onto the main polymer chain (the backbone).

In 2020, the Group launched a new division named GraftBio to develop IP for Bio/Pharma applications. This includes a drug delivery system to support and provide solutions to the market, which had been heavily impacted by the COVID-19 pandemic. The GraftBio division has been granted HACCP certification for its production facility. The Group has developed a set of drug delivery platforms that enable it to licence its DDS platform (IP) to MGC Pharmaceuticals Limited ("MGC"; LSE: MXC) in relation to MGC's CimetrA™ and CannEpil-IL™ products. The Group expects to receive royalty payments resulting from the sale by MGC of CimetrA™ and CannEpil-IL™ products.

 

END

 

 

NOAUSSVRUOUBRAR